The blood-saving effect of vasopressinergic V1 receptor agonists in urologic oncology
Objective: to investigate whether it is expedient to use the selective vasopressinergic V1 receptor agonist Remestyp® (terlipressin) to reduce the amount of blood loss and the duration of urologic cancer surgery.Materials and methods. Remestyp® was used as a selective vasopressor. The fact that the...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2017-10-01
|
| Series: | Onkourologiâ |
| Subjects: | |
| Online Access: | https://oncourology.abvpress.ru/oncur/article/view/715 |